Regionally, Americas held a Strong market share in 2018 and is projected to hold its position in the
global marketplace through the forecast period. Europe, on the other hand, is an important growth
pocket expected to reflect a high CAGR over the review period. The region is anticipated to witness
inflow of investments in research & development which is likely to favor the growth of the market.
Major Players profiled in the Epilepsy Market report incorporate: Eisai Co. Ltd, Novartis AG, Pfizer Inc,
GW Pharmaceuticals PLC, Abbott Laboratories, UCB SA, LivaNova PLC, Medtronic PLC, Johnson &
Johnson Services, GlaxoSmithKline PLC, and NeuroPace Inc.
Latest Industry News
1 GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), the world leader in
the development and commercialization of cannabinoid prescription medicines, along with its U.S.
subsidiary Greenwich Biosciences, announced today that EPIDIOLEX (cannabidiol) oral solution CV is
now available in the U.S. for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS)
or Dravet syndrome in patients two years of age or older. EPIDIOLEX, which was approved by the U.S.
Food and Drug Administration (FDA) on June 25, 2018, is the first prescription pharmaceutical
formulation of highly purified, plant-derived cannabidiol (CBD), a cannabinoid lacking the high
associated with marijuana, and the first in a new category of anti-epileptic drugs.
“EPIDIOLEX is a much-needed new treatment option for patients with LGS, a rare and severe form of
childhood-onset epilepsy that typically persists into adulthood,” said Christina SanInocencio, Executive
Director of the Lennox-Gastaut Syndrome Foundation. “Despite the use of multiple epilepsy treatments,
the majority of LGS patients continue to have life-long, debilitating seizures and our community
welcomes the availability of a new, first-in-class treatment option.”
2 Novartis announced that the US Food and Drug Administration (FDA) has approved Mayzent
(siponimod) for the treatment of adults with relapsing forms of multiple sclerosis, including secondary
progressive multiple sclerosis (SPMS) with active disease, relapsing remitting multiple sclerosis (RRMS)
and clinically isolated syndrome (CIS). SPMS is a debilitating form of multiple sclerosis (MS)
characterized by progressive and irreversible neurological disability. Mayzent is expected to be available
in the US in approximately one week. Patients will not require a first dose observation (FDO, cardiac
monitoring upon initiation) unless they have certain pre-existing cardiac conditions.
Request a Discount on standard prices of this premium report @
https://www.businessindustryreports.com/check-discount/162955 .
Region segment: This report is segmented into several key regions, with sales, revenue, market share
(%) and growth Rate (%) of Epilepsy in these regions, from 2014 to 2023 (forecast), covering: North
America, Europe, Asia Pacific, Middle East & Africa and South America.
Significant points in table of contents: Market Definition, Market Overview, Business Introduction,
Segmentation (Region Level), Segmentation (Type Level), Segmentation (Industry Level), Segmentation